PSILOTEC HEALTH SOLUTIONS - Key Persons
Mr. Darbellay has over 20-years experience working with global large cap Forbes 2000 public companies, as well as private start-ups. Mr. Darbellay most recently served as the Chief Financial Officer of a Canadian-based life sciences company focused on research, development, and commercialization of novel cannabinoid-based compounds for medical purposes. Prior to that, Mr. Darbellay worked with Nutrien (NYSE:NTR), the world's largest integrated producer and provider of crop nutrients and services, overseeing the global Finance Transformation function. Mr. Darbellay brings extensive leadership experience in corporate M&A, strategy, and deep financial expertise.
Job Titles:
- Chairman of Mood Disorders
Dr. Young is the Chair of Mood Disorders in the Institute of Psychiatry, Psychology and Neuroscience, and also currently serves as the Vice-Dean and Head of School of Academic Psychiatry, at King's College London, UK. Dr. Young's research interests focus on the cause and treatments for severe psychiatric illnesses, particularly mood disorders. Dr. Young has held academic appointments at Oxford University; Newcastle University (latterly holding the Chair of General Psychiatry at Newcastle), University of British Columbia in Vancouver, Canada, where he held the Leading Edge Endowment Fund Endowed Chair in Research in the Department of Psychiatry and was also the Director of the Institute of Mental Health and Imperial College London, where he held the Chair of Psychiatry and was Director of the Centre for Mental Health Dr Young has has received research grant funding from the UK Medical Research Council, the Wellcome Trust, the Stanley Medical Research Institute, the Canadian Institutes for Heath Research (CIHR), the National Institutes of Health (USA), and numerous other funding agencies. Dr. Young has published over 600 peer-reviewed publications and several books about psychopharmacology and affective disorders. Dr. Young was recently ranked as one of the world's leading scientific minds in the field of psychiatry and psychology, according to the Thomson Reuters Highly Cited Researchers list. In all of science, a total of just over 3,000 researchers worldwide earned this distinction, and the academics listed rank among the top one percent most cited for their subject field and year of publication, a mark of exceptional impact.
Dr. Pazderka has a long background of working in clinical research and project management within the field of psychiatry for over 20 years. Dr. Pazderka has been involved in multiple studies and project management of a variety of mental health initiatives. Dr. Hannah Pazderka received her PhD in Neuroscience from the University of Alberta in 2004, looking at indices of drug and alcohol craving. Since then, she has worked in a number of roles, including creation of public policy, research, and advocacy. Her primary research interests are in the regulation of impulsive and risk taking behaviour via the frontal lobes and subcortical reward structures. She has worked with a number of different methodologies, including structural equation modeling, electrophysiology (ERPs and skin conductance), neuropsychological assessment, and epidemiology.
Dr. Scott is the Founder, Owner, and Chief Scientific Officer of Sporometrics Inc., an independent laboratory and leading provider of basic and applied scientific research on biomedical, industrial, and environmental microbes. Dr. Scott's PhD in Mycology was earned through the Department of Botany at the University of Toronto in 2001. Dr. Scott's PhD thesis, ‘Studies on Indoor Fungi', is still held today as one of the most comprehensive treatments of the mycology of indoor microbes. Dr. Scott is a Professor in Occupational Hygiene with the Dalla Lana School of Public Health at the University of Toronto. Dr. Scott's many contributions in the field of mycology include research and publications for government agencies, private corporations, and professional bodies, which has established Dr. Scott as a world leader in fungal research and occupational hygiene.
Job Titles:
- Vice President, Data Science
Dr. Brown is a leading researcher in aspects of mental health and the brain, with publications in journals that are part of the Nature group. Dr. Brown has a strong background in psychopharmacology, project management of clinical studies, brain imaging techniques and computational psychiatry, and using artificial intelligence ("AI") in mental health. Dr. Brown is an associate of the world leading AI group, the Alberta Machine Intelligence Institute at the University of Alberta. Dr. Brown is the co-founder of Retain Labs Medical Inc., a company focused on technology-based training solutions for health professionals. Dr. Brown is a scientific reviewer for Frontiers in Systems in Neuroscience, Neuroimage and Experimental Brain Research. He received his PhD in neuroscience from the University of Western Ontario and was a research fellow in the Department of Psychiatry and Adjunct Professor in the Department of Computing Science at the University of Alberta.
Job Titles:
- Chief Executive Officer
- Director
Dr. Silverstone has a 35-year background in brain and pharmaceutical research. Dr. Silverstone has highly relevant expertise in international drug and IP development, digital mental health, regulatory matters, and has been involved in multiple health related start-up companies. Dr. Silverstone previously served as the Senior Vice President, Medical and Scientific Affairs of Biovail, one of Canada's largest publicly traded pharmaceutical companies with annual revenue in excess of a billion dollars, prior to its merger with Valeant Pharmaceutical International. Dr. Silverstone is currently the Interim Chair of the Department of Psychiatry at the University of Alberta. Dr. Silverstone received his MD at the University of London and spent three years as a research fellow at the University of Oxford. Dr. Silverstone's research achievements have won several awards and he has published over 120 peer-reviewed articles. Dr. Silverstone is the author of the The Promise of Psychedelics, available here or wherever you buy your books.
Dr. Chue has extensive experience in clinical psychopharmacology. Dr. Chue's experience includes acting as the Director of the Clinical Trials and Research Program, Alberta Health Services, and has been involved in over 50 national and international clinical trials in areas including depression, anxiety disorders and addiction. Dr. Chue is a researcher with the Integrative Health Institute, Centre of Excellence for Real World Clinical Outcomes and Campus Alberta Neuroscience (University of Alberta). Dr. Chue completed his medical degree (MBBCh) and psychiatric specialization (MRCPsych) in the UK before moving to Canada in 1991 where he subsequently obtained Canadian medical (LMCC) and specialist qualifications (FRCPC) as well as American Boards Certification in Psychiatry and Neurology (DABPN) and an MSc in Psychiatry at the University of Alberta. He was elected a Fellow of the Royal College of Psychiatrists (FRCPsych) in the UK in 2004.
Dr. Engels has a 27-years background working in behavioral and mental health and addictions, and has deep expertise in understanding, predicting, and treating various mental health conditions, as well as addictions. Dr. Engels has a PhD in Medical Sciences from the University of Maastricht, the Netherlands. Dr. Engels held various leadership positions at the Radboud University, Netherlands, including serving as the Vice-Dean for Research, and Director of the Behavioral Science Institute. Dr. Engels was appointed and served as Chairperson of the Executive Board of the Trimbos Institute, the National Institute for Mental Health and Addictions, and from 2018 to 2021, Dr. Engels was Rector Magnificus of the Erasmus University Rotterdam, where he was overall responsible for education, research, and strategy. In the last 15 years, Dr. Engels has led a series of randomized trials on digital mental health interventions in collaboration with both high standing academic institutions and companies in North America.
Dr. Goldstein most recently served as Chief Artificial Intelligence Officer with Elevance Health Inc. (ELV:NYSE), formerly Anthem Inc., where he oversaw the development of ‘HealthOS', an artificial intelligence-based health operating system. Dr. Goldstein was previously Vice President of Software Tools at Apple Inc. (AAPL:NASDAQ), where he led the team that created Xcode, Mac OS X, and iOS runtime operating systems for Mac and iPhone. Before Apple, Dr. Goldstein served as Chief Java Commerce Officer with Sun Microsystems, where he was a co-creator of the Java programming language and designed the Java Card system used in billions of smartcards. Dr. Goldstein holds a Ph.D. in Bioinformatics and Biomolecular Engineering from the University of California at Santa Cruz (UCSC) and has held faculty positions at UCSF and the University of California San Francisco medical school.
Job Titles:
- Chief Clinical Officer
- Member of the Qalipu Mi'Kmaq First Nation
Dr. Hillier is a proud member of the Qalipu Mi'kmaq First Nation and spent 20 years in the Canadian Armed Forces as a physician. During this time Dr. Hillier gained extensive experience in working with patients with PTSD, Depression, Anxiety, and Addictions, the four key areas of clinical focus for Zylorion. Additionally, Dr. Hillier gained expertise in international logistics in the medical field, working in multiple countries in a wide variety of roles. She trained at a master's level in clinical trial methodology, and also at the Master's level in Education. Dr. Hillier has led the development of a complex computerized medical training system, and oversaw its successful implementation, in a world- renowned university. Her most recent role was as Director and Executive Dean, Alberta Institute Wenzhou Medical University, an international collaborative start-up between the University of Alberta and a leading Chinese medical facility.
Dr. Suppes has an extensive background in psychiatry and recognized expert on mood disorders, particularly major depressive disorder and bipolar disorder. Dr. Suppes areas of specialization include long-term treatment strategies for bipolar disorder, identification and treatment of bipolar II disorder, the use of complementary medicine for bipolar disorder, and has recently launched a new initiative to explore use of psychedelics for psychiatric disorders. Dr. Suppes is a Professor of Psychiatry and Behavioral Science at Stanford University, and a member of Bio-X, Stanford's interdisciplinary biosciences institute. Dr. Suppes was the Chair of the U.S. Department of Defense, Veteran Affairs guidelines for bipolar disorder, and the Bipolar module of the Texas Medication Algorithm Project. In addition, Dr. Suppes is also Director of the Exploratory Therapeutics Laboratory and the founder of the Bipolar and Depression Research Program at the VA Palo Alto Health Care System. Dr. Suppes has over 250 publications and received numerous awards and recognition for contributions to her field. Ranked one of the leading scientific minds in the field of psychiatry and psychology, Thomson Reuters Highly Cited Researchers.
Dr. Greenleaf is a behavioral neuroscientist and a medical technology developer working at Stanford University. With over three decades of research and development experience in the field of digital medicine and medical virtual reality technology, he is considered the leading authority in the field. Dr. Greenleaf has designed and developed numerous clinical systems over the last thirty-five years, including products in the fields of: surgical simulation, 3D medical visualization, telerehabilitation, clinical informatics, clinical decision support, point-of-care clinical data collection, ergonomic evaluation technology, automatic sleep-staging systems, psychophysiological assessment, and simulation-assisted rehabilitation technologies, as well as products for behavioral medicine. Dr. Greenleaf is currently a Distinguished Visiting Scholar at Stanford University's MediaX Program, a Visiting Scholar at Stanford University's Virtual Human Interaction Lab, and the Director of Technology Strategy at the University of Colorado National Mental Health Innovation Center. Dr. Greenleaf is a member of the Board of Directors for Brainstorm: The Stanford Laboratory for Brain Health Innovation and Entrepreneurship and for Sine Wave, the developer of Sine Space, a multi-user online Unity 3D-based virtual world platform, and Cognitive Leap. In addition to his research at Stanford University, Dr. Greeleaf is Senior Vice President of Strategic & Corporate Affairs to MindMaze, a global leader in brain technology, and Chief Science Advisor to Pear Therapeutics, a biotech company that develops digital therapeutics to treat disease and enhance the efficacy of pharmaceuticals. Dr. Greenleaf is a virtual reality technology and neuroscience advisor to several early-stage medical product companies, including MindStrong Health, Ellipsis Health, Limbix, Tripp, eQuility, Altoida, MyndVR, OramaVR, and BehaVR. Dr. Greenleaf earned a Doctorate in Neuro and Bio-Behavioral Sciences from the Stanford University School of Medicine, where he was awarded an NIMH Graduate Fellowship.
Job Titles:
- Director
- Innovation Leader
- Strategic Advisor & Board Observer
Mr. Tas is an innovation leader who applies his entrepreneurship, experience in large scale digital transformation and expertise in information technology (Cloud, AI, IoT, cyber security) to transform and grow businesses. In Mr. Tas' 10-year tenure at Koninklijke Philips N.V. (NYSE:PHG;AMS:PHIA), in the role of Chief Innovation and Strategy Officer, Mr. Tas was instrumental in the transition of Philips to a customer-centric, digital health tech solutions company. Before joining Philips, Mr. Tas co-founded and served as President, COO and Vice-Chairman of the Board for Mphasis, a technology solutions company focused on services for the financial industry, which was acquired by HP (EDS) in 2006. Mr. Tas is the 2004 winner of the E&Y Entrepreneur of the Year Award in the Information Technology category for the New York region. Mr. Tas was also the recipient of the 2013 Dutch CIO of the year award, NASSCOM 2014 Global CIO award, the World Innovation Congress 2014 CIO Leadership award, the CIONet 2014 European CIO award, the IT Executive 2014 award, and the Accenture 2015 Innovator of the Year award. Mr. Tas is a native of the Netherlands and holds a Master's degree in Computer Science and Business Administration from the Vrije University, Amsterdam.
Job Titles:
- Director
- CEO of 22nd Century Group, Inc
Mr. Mish is currently the CEO of 22nd Century Group, Inc., a leading plant biotechnology company focused on technologies that alter the level of cannabinoids in hemp/cannabis plants through genetic engineering, gene editing and modern plant breeding. Mr. Mish has an outstanding 35-year track record of delivering profitable growth at both privately held and publicly traded companies with a focus on pharmaceutical and consumer products. Prior thereto, Mr. Mish served as President and CEO of Purisys, a synthetic cannabinoid API, ingredients and solutions provider to pharmaceutical and consumer products companies, and Noramco, a global leader in the production of controlled substances for the pharmaceutical industry. Mr. Mish is a graduate from the Pennsylvania State University in Chemistry and The University of Pennsylvania, Wharton School of Business.
Job Titles:
- Senior Therapeutic Counsellor
Krystal Davidson has extensive experience treating patients with a wide variety of mental health conditions. This includes a large range of diverse individuals across all age ranges. She has utilized these skills in training programs both online and in-person. She was the lead therapist for a major online initiative during the COVID-19 pandemic, working alongside Dr. Silverstone, which supported over 5,000 individuals during 2020. She graduated originally from Thompson Rivers University and is a registered social worker and a certified therapist. Krystal joined the Zylorion team at inception and has been intimately involved in her role as a Senior Therapeutic Counsellor in actively supporting development of all aspects of the Almond Therapy program, including authoring many aspects of the workbook.
Job Titles:
- Senior Clinical Trial Manager
Lee-Ann Langkaas has over 15 years of clinical trials experience in multiple areas including Clinical Trial Management, Regulatory Compliance, Leadership, Policy, Standard Operating Procedure Development and Quality Assurance. She also has strong financial clinical trial expertise, ensuring that each project is carried out in the most cost-effective manner. Lee-Ann has significant experience in interactions with sponsors, CROs, vendors, clinical investigators, and regulatory agencies. She has managed complex clinical trials in multiple therapeutic areas across all phases. Most recently Lee-Ann was working as a Research Manager with an internationally recognized expert group of researchers at the University of Alberta managing multiple trials from start up to close out. Lee-Ann joined Zylorion as a Senior Clinical Trials Manager and has been actively involved in the development of the clinical trials program.
Job Titles:
- Chief Risk Officer
- Co - Founder and Managing Director of Lightyear Capital Inc
Ms. Duchesne is co-founder and Managing Director of Lightyear Capital Inc., a privately held full-service, IIROC member, investment dealer. Ms. Duchesne has over 30-years of capital markets, finance, accounting, tax, regulatory compliance, and investment industry experience. Prior to co-founding Lightyear, Ms. Duchesne was the Chief Financial Officer and Director of an independent investment dealer. Ms. Duchesne holds a Bachelor of Commerce from McGill University and a CPA, CA designation.
Ms. Beth Rogozinski is a serial entrepreneur, technology innovator, and business strategist with a background in digital medicine and medical devices. Ms. Rogozinski has worked in information technology hardware, software, and services with leading technology companies, including Silicon Graphics, Macromedia, and the digital agency Circle. Ms. Rogozinski has also founded digital gaming and application development companies including Signal 2 Productions, Match Factor and D2S Games. Ms. Rogozinski has produced and published over a dozen software applications focused on health and wellness. As Chief Product Officer at Pear Therapeutics Inc. ("Pear"), Ms. Rogozinski led the development of Pear's first clinical products and submission of the De Novo 510k to the U.S. Food and Drug Administration (the "FDA"). Pear's ReSET™ was cleared by the FDA in 2017 as the first ever prescription digital therapeutic. Ms. Rogozinski is a director and advisor to a number of high growth start-up companies and accelerators, and has consulted with numerous health and innovation centers, such as Stanford University, UnitedHealth Group, and the National Mental Health Innovation Center. Ms. Rogozinski is currently the Chief Executive Officer of Oncoustics, an innovative artificial intelligence solutions company that is creating low cost, non-invasive surveillance, diagnostics, and treatment monitoring for diseases with high unmet clinical needs.
Job Titles:
- Chairman
- Director
- Co - Founder and Managing Director of Lightyear Capital Inc
Mr. Weimer is co-founder and Managing Director of Lightyear Capital Inc. ("Lightyear"), a privately held full-service, IIROC member, investment dealer. Mr. Weimer oversees all aspects of Lightyear's investment banking initiatives and Lightyear's merchant banking division. Over Mr. Weimer's 25-year career he has supported the start up and growth of multiple companies in a diverse range of business lines and has executed on numerous M&A, valuation, equity and debt financing assignments. As Chairman of PsiloTec, Mr. Weimer is actively involved in all aspects of PsiloTec's business strategy along with providing leadership on executing PsiloTec's capital markets strategy. Mr. Weimer holds a Bachelor of Commerce from the University of Saskatchewan and a CPA, CA designation.
Ms. Kranz has extensive experience in disruptive interventions and technologies through a 20-year career in U.S. Military Intelligence with Special Operations Forces and the Federal Bureau of Investigation (FBI). Ms. Kranz is the Founder and Chief Executive Officer of Medi-XR, a digital health therapeutics consulting firm based in North Carolina, and currently serves as an embedded executive in support of the Novant Health Chief Transformation and Digital Office's Innovation and Artificial Intelligence Institute where Ms. Kranz leads innovation efforts in the digital health transformation space. Ms. Kranz previously served as Deputy Director of the Tufts University Counter Terrorism Center, a former research associate at Harvard University, and was an instructor at the U.S. Military Academy. Ms. Kranz holds an MBA from Oxford University, with a focus on disruptive healthcare interventions. Ms. Kranz serves on the steering committees for the North Carolina Biotech Health Innovation Summit, RevTech Labs Venture Capital Health Tech Conference, the Medical Device Innovation Consortium's XR in Healthcare, and as an advisor the U.S. Food and Drug Administration (FDA) on adoption of immersive technology as a digital therapeutic tool.
Mr. Rogers has built, over five decades, a renowned international reputation for the education and promotion of medical mushrooms. Mr. Rogers has been a ethnomycologist and clinical herbalist for nearly 50 years and is presently a Clinical Professor in family medicine at the University of Alberta, and Adjunct Professor in graduate studies at York University. Mr. Rogers has published over 50 books on plant and mushroom medicine, including ‘The Fungal Pharmacy: The Complete Guide to Medicinal Mushrooms and Lichens of North America'; and in 2020 he published ‘Medicinal Mushrooms: The Human Clinical Trials'. Over the past 30 years, Mr. Rogers has taught plant and mushroom medicine at various post-secondary institutions and has formulated many mushroom-based supplements in the natural health products industry. Mr. Rogers previously chaired the Alberta Natural Health Agricultural Network, and Capital Health Community Health Council, and served on the editorial board of the International Journal of Medicinal Mushrooms.
Job Titles:
- Corporate Secretary
- Senior Partner With Blake
Mr. Clarke is a senior partner with Blake, Cassels & Graydon LLP, with 24-years experience focused on mergers and acquisitions, power projects, corporate finance, private equity and governance matters (including ESG). Mr. Clarke's diverse public and private company client base spans life sciences, technology, power (with a focus on alternative energy), oil and gas services and exploration. Mr. Clarke is recognized as a leading lawyer in the Legal 500 Canada, Chambers Canada: Canada's Leading Lawyers for Business, the Best Lawyers in Canada, the Canadian Legal Lexpert Directory, and Acritas Stars. Mr. Clarke is also a member of the Securities Advisory Committee of the Alberta Securities Commission.
Mr. Phillips has over 20-years leadership experience in operations across several different industries. Most recently, Mr. Phillips was Assistant Chair, for the Department of Psychiatry at the University of Alberta where he worked directly with mental health education and service delivery. Prior to that, Mr. Phillips led the logistics network for Canada's third largest private lab, with a team of over 65 employees and contracts covering Western Canada. Mr. Phillips has led multi million-dollar start-ups with focus on both the domestic and international markets, specifically in the technology and fabrication space. Mr. Phillips gained his MBA from Cornell University and maintains a CPA, CMA designation, as well as a PMP designation. In 2019, Mr. Phillips was named one of the Top 40 under 40 in Edmonton, Alberta.
Job Titles:
- Vice President, Business Development
Mr. Boekhoff is an experienced entrepreneur and international business developer with a demonstrated history of building and growing companies in the healthcare and technology industry in the United States and the European Union. Mr. Boekhoff holds a Master of Business Administration from the Rotterdam School of Management. Mr. Boekhoff has worked and lived in Germany, Amsterdam, Vienna, Rome, Montreal, and San Francisco Bay Area, and is fluent in French, German, English and Dutch.
Mr. Cotter is a microbiologist and professional mycologist. Mr. Cotter specializes in organic horticulture, tissue culturing, and has more than 22 years experience cultivating and studying native fungi to the Southeast United States. Mr. Cotter lectures throughout North America, focusing his efforts on perpetual methods of mushroom cultivation. Mr. Cotter has undertaken numerous studies to explore applications for mushrooms in various industries and currently maintains over 200 species of fungi for food production and mycoremediation of environmental pollutants. Mr. Cotter has been the focus of interviews and documentaries in various media, including National Geographic. Mr. Cotter is the Designer and Chief Instructor of the North American Wild Mushroom Safety Certification Program and is a key contact for the North American Mycological Association Emergency Mushroom Toxicology group.